Opendata, web and dolomites

SWEETBULLETS SIGNED

Sweet Theranostics in Bitter Infections - Seek and Destroy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SWEETBULLETS project word cloud

Explore the words cloud of the SWEETBULLETS project. It provides you a very rough idea of what is the project "SWEETBULLETS" about.

pathogens    treatment    patients    resistance    cargo    bacteria    ligand    nosocomially    pathogen    alarmingly    chronic    global    pathogenic    pace    drugs    nano    negative    vitro    infection    directed    infections    noninvasive    empty    ing    fight    site    employing    aeruginosa    mechanism    exposed    release    spp    tissue    acting    sweetbullets    efficiency    lectindirecting    conjugates    envelope    smart    anti    highest    contact    sweet    probes    gram    vivo    appropriate    extracellular    linking    bacterial    charging    gap    pseudomonas    fibrosis    resistances    groups    lectin    noncovalent    demanding    carriers    threat    cleavable    binding    ligands    carbohydrate    proof    linker    appearance    eskape    klebsiella    overcome    wp2    conjugation    optimization    imaging    clinically    bactericidal    deleterious    relief    enzymes    wp1    biofilm    theranostics    linkers    drug    resistant    packages    protective    infected    boost    covalent    efficacy    cellular    therapy    manufacturing    successful    pipeline    surface    potency    wp3    extendable    cystic    treatments    fundamentally    antibiotics    intracellularly    proteins    inhibitor   

Project "SWEETBULLETS" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH 

Organization address
address: INHOFFENSTRASSE 7
city: BRAUNSCHWEIG
postcode: 38124
website: www.helmholtz-hzi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙551 €
 EC max contribution 1˙499˙551 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2022-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) coordinator 1˙499˙551.00

Map

 Project objective

Bacterial infections are now a global threat demanding novel treatments due to the appearance of resistances against antibiotics at a high pace. The ESKAPE pathogens are those with highest importance in the EU and chronic infections due to biofilm formation are a particular task. Noninvasive pathogen-specific imaging of the infected tissue is not clinically available. Its successful implementation will enable the choice of appropriate therapy and boost efficacy. Furthermore, Gram-negative bacteria have a highly protective cellular envelope as an important resistance mechanism for drugs acting intracellularly, resulting in an alarmingly empty drug-pipeline. To overcome this gap, I will establish Lectin-directed Theranostics targeting pathogens via their extracellular carbohydrate-binding proteins at the site of infection for specific imaging and treatment. This will be implemented for the highly resistant ESKAPE pathogen Pseudomonas aeruginosa through 3 different work packages. WP1 Sweet Imaging: Design & conjugation of lectin-directed ligands to imaging probes, Optimization of ligand/linker, in vivo proof-of-concept imaging study. WP2 Sweet Targeting: Delivery of antibiotics to the infection through covalent linking of lectindirecting groups. Employing different antibiotics, assessment of bactericidal potency and targeting efficiency. Manufacturing of nano-carriers with surface exposed lectin-directed ligands, noncovalent charging with antibiotics. In vitro and in vivo targeting. WP3 Sweet SMART Targeting: Conjugates as SMART drugs: specific release of anti-biofilm lectin inhibitor and drug cargo upon contact with pathogen, development of linkers cleavable by pathogenic enzymes. SWEETBULLETS will establish fundamentally novel lectin-directed theranostics to fight these deleterious infections and provide relief to nosocomially infected and cystic fibrosis patients. It is rapidly extendable towards other ESKAPE pathogens, e.g. Klebsiella spp..

 Publications

year authors and title journal last update
List of publications.
2019 Roman Sommer, Katharina Rox, Stefanie Wagner, Dirk Hauck, Sarah S. Henrikus, Shelby Newsad, Tatjana Arnold, Thomas Ryckmans, Mark Brönstrup, Anne Imberty, Annabelle Varrot, Rolf W. Hartmann, Alexander Titz
Anti-biofilm Agents against Pseudomonas aeruginosa : A Structure–Activity Relationship Study of C -Glycosidic LecB Inhibitors
published pages: 9201-9216, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01120
Journal of Medicinal Chemistry 62/20 2020-04-24
2017 Stefanie Wagner, Dirk Hauck, Michael Hoffmann, Roman Sommer, Ines Joachim, Rolf Müller, Anne Imberty, Annabelle Varrot, Alexander Titz
Covalent Lectin Inhibition and Application in Bacterial Biofilm Imaging
published pages: 16559-16564, ISSN: 1433-7851, DOI: 10.1002/anie.201709368
Angewandte Chemie International Edition 56/52 2019-04-03

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SWEETBULLETS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SWEETBULLETS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SUExp (2018)

Strategic Uncertainty: An Experimental Investigation

Read More  

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More  

RTMFRM (2019)

Room Temperature Magnetic Resonance Force Microscopy

Read More